content
This site is intended for U.S. healthcare professionals.
image
content
disclaimer
mCRC, metastatic colorectal cancer.
BRAF-mutant mCRC has double the bite—patients with this mutation progress ~2x quicker compared to those with wild-type BRAF mCRC1,2
In a planned subgroup analysis of a phase 3 randomized trial, patients with BRAF-mutant mCRC experienced:
~2x faster progression compared to those with wild-type BRAF mCRC1
Less than half the median overall survival compared to those with wild-type BRAF mCRC1
The subgroup population (N=357) included 28 patients with BRAF mutations, 236 with RAS mutations, and 93 with wild-type BRAF and RAS mCRC.1
- With an estimated 8%-12% of patients with mCRC harboring a BRAF mutation, testing at diagnosis is critical to help inform treatment planning3,4
Testing at diagnosis can help you
ACT FASTER to identify patients with BRAF-mutant mCRC
A rapid testing method can help give the full clinical picture, including BRAF mutations and other poor prognosis predictors, as you plan for treatment.3,5,6
- NCCN GUIDELINES®
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend testing all patients with mCRC at initial workup7,8
icon
content
Learn how to test more quickly for BRAF-mutant mCRC
icon
content
Resources and common questions about testing
NCCN, National Comprehensive Cancer Network® (NCCN®); RAS, rat sarcoma virus GTPase.
References
content
- Cremolini C, Loupakis F, Antoniotti C, et al. Lancet Oncol. 2015;16(13):1306-1315.
- Cohen R, Liu H, Fiskum J, et al. J Natl Cancer Inst. 2021;113(10):1386-1395.
- Van Cutsem E, Cervantes A, Adam R, et al. Ann Oncol. 2016;27(8):1386-1422.
- Tabernero J, Ros J, Élez E. Am Soc Clin Oncol Educ Book. 2022;42:254-263.
- Kopetz S, Grothey A, Yaeger R, et al. N Engl J Med. 2019;381(17):1632-1643.
- Benavides M, Alcaide-Garcia J, Torres E, et al. ESMO Open. 2022;7(3):100481.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 7, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.